Company Description
SciSparc Ltd., a clinical-stage pharmaceutical company, develops drugs based on cannabinoid therapies.
Its drug development programs include SCI-110 for the treatment of Tourette syndrome and Alzheimer’s disease and agitation; SCI-210 for the treatment of autism spectrum disorder and status epilepticus; and CannAmide, an anti-inflammatory and chronic pain solution.
It also sells hemp seed oil-based products and others. The company has an agreement with Procaps to develop and commercially manufacture SCI-110, palmitoylethanolamide oral tablets and CannAmide in softgel capsule form.
It also has an agreement with The Israeli Medical Center for Alzheimer’s to conduct a phase IIa clinical trial to evaluate the safety, tolerability, and efficacy of SCI-110 in patients with Alzheimer’s disease and agitation; and a collaboration with Clearmind Medicine Inc. The company was formerly known as Therapix Biosciences Ltd. and changed its name to SciSparc Ltd. in January 2021.
SciSparc Ltd. was incorporated in 2004 and is headquartered in Tel Aviv-Yafo, Israel.
| Country | Israel |
| Founded | 2004 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 2 |
| CEO | Oz Adler |
Contact Details
Address: Tower A, 2nd Floor Tel Aviv, 6971916 Israel | |
| Phone | 972 7 334 47180 |
| Website | scisparc.com |
Stock Details
| Ticker Symbol | SPRC |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001611746 |
| CUSIP Number | M82618121 |
| ISIN Number | ILM826181218 |
| SIC Code | 5500 |
Key Executives
| Name | Position |
|---|---|
| Oz Adler CPA | Chief Executive Officer and Chief Financial Officer |
| Itschak Shrem | President and Director |
| Dr. Adi Zuloff-Shani Ph.D. | Chief Technologies Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Aug 8, 2025 | 6-K | Report of foreign issuer |
| Jul 31, 2025 | 6-K | Report of foreign issuer |
| Jul 30, 2025 | EFFECT | Notice of Effectiveness |
| Jul 22, 2025 | F-3/A | Filing |
| Jul 22, 2025 | 6-K | Report of foreign issuer |
| Jul 22, 2025 | 6-K | Report of foreign issuer |
| Jul 21, 2025 | EFFECT | Notice of Effectiveness |
| Jul 21, 2025 | 424B3 | Prospectus |
| Jul 8, 2025 | F-4/A | Filing |
| Jun 26, 2025 | 6-K | Report of foreign issuer |